A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies

NCT01121991 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Infertility
Ovarian Stimulation

Interventions

DRUG: Recombinant Human-Luteinizing Hormone (Luveris)

Sponsor

EMD Serono